Prebiotic Formulation with 2'-FLol from Reducing Fermentation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional processes produce low levels of 2'-fucosyllactitol (2'-FLol) as a byproduct during microbial fermentation of 2'-fucosyllactose (2'-FL), limiting the development of robust prebiotic systems that require increased levels of both compounds for optimal gut health benefits.

Innovation Solution

A process involving microbial fermentation under reducing conditions to produce 2'-FLol at increased levels, followed by isolation, purification, and concentration steps to form a prebiotic solids product containing 0.5 to 6.0 wt.% 2'-FLol and 86.0 to 94.0 wt.% 2'-FL, with optional heat treatment to deactivate microorganisms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional microbial fermentation is used to produce 2'-FL, then 2'-FL production is achieved, but 2'-FLol levels remain low as only a minor byproduct

Engineering Contradiction:
Improve2'-FLol concentrationVSAvoidfermentation efficiency
Core Design Contradiction:
Quantity of substanceVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the redox potential of the fermentation medium through the addition of reducing agents (ascorbic acid, dithiothreitol, or dithioerytritol at concentrations of 0.1-10 mM). This chemical parameter modification shifts the fermentation metabolism to increase 2'-FLol production from trace levels to 0.5-6.0 wt.% of the total prebiotic solids, directly resolving the contradiction between maintaining fermentation productivity and increasing 2'-FLol quantity.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If 2'-FL is used alone as a prebiotic, then prebiotic effect is provided, but the system lacks robustness against premature hydrolysis during storage or meal preparation

Engineering Contradiction:
Improveprebiotic system robustnessVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a composite prebiotic material system by combining 2'-FL with 2'-FLol in specific ratios (0.5-6.0 wt.% 2'-FLol with 86.0-94.0 wt.% 2'-FL). This composite formulation provides functional robustness because 2'-FLol serves as a stable reservoir that can be hydrolyzed to 2'-FL in the gut, ensuring prebiotic activity is maintained even if some 2'-FL degrades during storage or preparation. The complexity increase is minimal, involving only compositional adjustment rather than structural complexity.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process effectively produces a prebiotic formulation with enhanced levels of 2'-FLol, ensuring stability and efficacy in stimulating beneficial gut microbiota, providing a more robust prebiotic system than 2'-FL alone, and supporting healthy digestive tract development in infants.

Implementation Method 1

2'-FL is typically produced in microbial fermentation reactors

Methodology Applied
Scientific EffectFermentation: Fermentation

Implementation Method 2

subjected to reducing conditions to produce 2'-FLol

Methodology Applied
Scientific EffectReduction: Reduction

Data Source

PatentEP4258901B1Improved prebiotic formulations
Publication Date: 2025.09.24 DSM IP ASSETS BV
  • EP4258901B1 patent drawingFigure 1
  • EP4258901B1 patent drawingFigure 2~3
  • EP4258901B1 patent drawingFigure 4~5

AI summary

Process comprising reducing a fermentation broth comprising 2'-fucosyllactose to produce a treated fermentation broth comprising 2'-fucosyllactose and 2'-fucosyllactitol; isolating a stream comprising 2'-fucosyllactose and 2'-fucosyllactitol from the treated fermentation broth; purifying the isolated stream; concentrating the purified isolated stream; dewatering the concentrated purified isolated stream, thereby forming a prebiotic solids product comprising 2'-fucosyllactose and 0.2 to 6.0 wt.% of 2'-fucosyllactitol based on the total wt.% of the prebiotic solids product, wherein the concentrating step and dewatering step can be performed in any order.